Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Canady Helios Cold Plasma (CHCP) is a medical device that delivers non-thermal (room temperature) cold atmospheric plasma (CAP) and an electromagnetic field to target cancer cells. The system generates reactive oxygen species (ROS), reactive nitrogen species (RNS), and a specific electromagnetic field called the Plasma Treatment Electromagnetic Field (PTEF). These components selectively disrupt cellular homeostasis in cancer cells, leading to cell cycle interruption, reduced viability, and apoptosis without damaging normal tissue. The technology is primarily used as an adjuvant therapy after surgical removal of solid tumors to eliminate microscopic residual cancer cells at the margins[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Canady Helios Cold Plasma.